Sabby Management’s Citius Pharmaceuticals CTXR Stock Holding History

Sabby Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,235	Closed	-$48K	–	162
2021 Q4	$48K	Buy	+1,235	New	+$56K	0.01%	169
2021 Q2	–	Sell	-12,560	Closed	-$559K	–	173
2021 Q1	$559K	Buy	+12,560	New	+$500K	0.11%	103
2020 Q4	–	Sell	-3,548	Closed	-$92K	–	123
2020 Q3	$92K	Buy	+3,548	New	+$100K	0.01%	118
2020 Q2	–	Sell	-54,171	Closed	-$813K	–	108
2020 Q1	$813K	Buy	+54,171	New	+$1.14M	0.34%	28
2019 Q4	–	Sell	-33,817	Closed	-$640K	–	78
2019 Q3	$640K	Buy	+33,817	New	+$892K	0.34%	30
2019 Q1	–	Sell	-1,122	Closed	-$29K	–	92
2018 Q4	$29K	Buy	1,122 +659	+142%	+$22.6K	0.01%	104
2018 Q3	$20K	Sell	463 -15,824	-97%	-$756K	﹤0.01%	117
2018 Q2	$937K	Sell	16,287 -9,361	-36%	-$622K	0.14%	61
2018 Q1	$1.99M	Buy	25,648 +17,243	+205%	+$1.59M	0.24%	38
2017 Q4	$820K	Buy	+8,405	New	+$842K	0.07%	86

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Sabby Management's CTXR Position: Q1 2022 in Review

Sabby Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 1,235 shares — an estimated $48K sold.

Sabby Management first reported a position in CTXR in Q4 2017 and held it in 10 quarters. The position peaked at $1.99M in Q1 2018. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

Sabby Management reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 1,235 Citius Pharmaceuticals shares in Q1 2022, an estimated $48K.
Sabby Management first reported a position in Citius Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Sabby Management's Citius Pharmaceuticals position peaked at $1.99M in Q1 2018.
76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.